Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.

<h4>Objective</h4>To assess the feasibility, safety and precision of organ-based tracking (OBT)-fusion targeted focal microwave ablation (FMA), in patients with low to intermediate risk prostate cancer.<h4>Patients and method</h4>Ten patients with a visible index tumor of Gle...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicolas Barry Delongchamps, Alexandre Schull, Julien Anract, Jean-Paul Abecassis, Marc Zerbib, Mathilde Sibony, Léa Jilet, Hendy Abdoul, Vincent Goffin, Michaël Peyromaure
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/50141246603f4b8d862722c30eafdc00
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:50141246603f4b8d862722c30eafdc00
record_format	dspace
spelling	oai:doaj.org-article:50141246603f4b8d862722c30eafdc002021-12-02T20:05:04ZFeasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.1932-620310.1371/journal.pone.0252040https://doaj.org/article/50141246603f4b8d862722c30eafdc002021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252040https://doaj.org/toc/1932-6203<h4>Objective</h4>To assess the feasibility, safety and precision of organ-based tracking (OBT)-fusion targeted focal microwave ablation (FMA), in patients with low to intermediate risk prostate cancer.<h4>Patients and method</h4>Ten patients with a visible index tumor of Gleason score ≤3+4, largest diameter <20mm were included. Transrectal OBT-fusion targeted FMA was performed using an 18G needle. Primary endpoint was the evidence of complete overlap of the index tumor by ablation zone necrosis on MRI 7 days after ablation. Urinary and sexual function were assessed with IPSS, IIEF5 and MSHQ-EjD-SF. Oncological outcomes were assessed with PSA at 2 and 6 months, and re-biopsy at 6 months.<h4>Results</h4>Median [IQR] age was 64.5 [61-72] years and baseline PSA was 5 [4.3-8.1] ng/mL. Seven (70%) and 3 (30%) patients had a low and intermediate risk cancer, respectively. Median largest tumor axis was of 11 [9.0-15.0] mm. Median duration of procedure was of 82 [44-170] min. No patient reported any pain or rectal bleeding, and all 10 patients were discharged the next day. Seven days after ablation, total necrosis of the index tumor on MRI was obtained in eight (80% [95%CI 55%-100%]) patients. One patient was treated with radical prostatectomy. Re-biopsy at 6 months in the other 9 did not show evidence of cancer in 4 patients. IPSS, IIEF-5 and MSHQ-EjD-SF were not statistically different between baseline and 6 months follow up.<h4>Conclusions</h4>OBT-fusion targeted FMA was feasible, precise, and safe in patients with low to intermediate risk localized prostate cancer.Nicolas Barry DelongchampsAlexandre SchullJulien AnractJean-Paul AbecassisMarc ZerbibMathilde SibonyLéa JiletHendy AbdoulVincent GoffinMichaël PeyromaurePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0252040 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nicolas Barry Delongchamps Alexandre Schull Julien Anract Jean-Paul Abecassis Marc Zerbib Mathilde Sibony Léa Jilet Hendy Abdoul Vincent Goffin Michaël Peyromaure Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
description	<h4>Objective</h4>To assess the feasibility, safety and precision of organ-based tracking (OBT)-fusion targeted focal microwave ablation (FMA), in patients with low to intermediate risk prostate cancer.<h4>Patients and method</h4>Ten patients with a visible index tumor of Gleason score ≤3+4, largest diameter <20mm were included. Transrectal OBT-fusion targeted FMA was performed using an 18G needle. Primary endpoint was the evidence of complete overlap of the index tumor by ablation zone necrosis on MRI 7 days after ablation. Urinary and sexual function were assessed with IPSS, IIEF5 and MSHQ-EjD-SF. Oncological outcomes were assessed with PSA at 2 and 6 months, and re-biopsy at 6 months.<h4>Results</h4>Median [IQR] age was 64.5 [61-72] years and baseline PSA was 5 [4.3-8.1] ng/mL. Seven (70%) and 3 (30%) patients had a low and intermediate risk cancer, respectively. Median largest tumor axis was of 11 [9.0-15.0] mm. Median duration of procedure was of 82 [44-170] min. No patient reported any pain or rectal bleeding, and all 10 patients were discharged the next day. Seven days after ablation, total necrosis of the index tumor on MRI was obtained in eight (80% [95%CI 55%-100%]) patients. One patient was treated with radical prostatectomy. Re-biopsy at 6 months in the other 9 did not show evidence of cancer in 4 patients. IPSS, IIEF-5 and MSHQ-EjD-SF were not statistically different between baseline and 6 months follow up.<h4>Conclusions</h4>OBT-fusion targeted FMA was feasible, precise, and safe in patients with low to intermediate risk localized prostate cancer.
format	article
author	Nicolas Barry Delongchamps Alexandre Schull Julien Anract Jean-Paul Abecassis Marc Zerbib Mathilde Sibony Léa Jilet Hendy Abdoul Vincent Goffin Michaël Peyromaure
author_facet	Nicolas Barry Delongchamps Alexandre Schull Julien Anract Jean-Paul Abecassis Marc Zerbib Mathilde Sibony Léa Jilet Hendy Abdoul Vincent Goffin Michaël Peyromaure
author_sort	Nicolas Barry Delongchamps
title	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
title_short	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
title_full	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
title_fullStr	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
title_full_unstemmed	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
title_sort	feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: results of the fostine trial.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/50141246603f4b8d862722c30eafdc00
work_keys_str_mv	AT nicolasbarrydelongchamps feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT alexandreschull feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT julienanract feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT jeanpaulabecassis feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT marczerbib feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT mathildesibony feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT leajilet feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT hendyabdoul feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT vincentgoffin feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial AT michaelpeyromaure feasibilityandsafetyoftargetedfocalmicrowaveablationoftheindextumorinpatientswithlowtointermediateriskprostatecancerresultsofthefostinetrial
_version_	1718375478928080896

Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.

Ejemplares similares